Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura; Dominik Hlauschek; Mafalda Oliveira; Dimitrios Zardavas; Anita Jallitsch-Halper; Lorena de la Peña; Paolo Nuciforo; Alberto Ballestrero; Peter Dubsky; Janine M Lombard; Peter Vuylsteke; Carlos A Castaneda; Marco Colleoni; Giuliano Santos Borges; Eva Ciruelos; Monica Fornier; Katalin Boer; Aditya Bardia; Timothy R Wilson; Thomas J Stout; Jerry Y Hsu; Yi Shi; Martine Piccart; Michael Gnant; José Baselga; Evandro de Azambuja

doi:10.1016/s1470-2045(19)30334-1

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30334-1 ◽

2019 ◽

Vol 20 (9) ◽

pp. 1226-1238 ◽

Cited By ~ 20

Author(s):

Cristina Saura ◽

Dominik Hlauschek ◽

Mafalda Oliveira ◽

Dimitrios Zardavas ◽

Anita Jallitsch-Halper ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Oestrogen Receptor ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00106-6 ◽

2016 ◽

Vol 17 (6) ◽

pp. 811-821 ◽

Cited By ~ 140

Author(s):

Ian E Krop ◽

Ingrid A Mayer ◽

Vinod Ganju ◽

Maura Dickler ◽

Stephen Johnston ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Oestrogen Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text

Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer

10.1158/1538-7445.sabcs14-ot1-1-01 ◽

2015 ◽

Author(s):

Cristina Saura ◽

Evandro de Azambuja ◽

Peter Dubsky ◽

Mafalda Oliveira ◽

Kamal S Saini ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Early Stage ◽

Blind Study ◽

Early Stage Breast Cancer ◽

Double Blind Study ◽

Double Blind ◽

Er Positive

Download Full-text

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

10.1158/1538-7445.sabcs17-ot3-06-01 ◽

2018 ◽

Cited By ~ 1

Author(s):

PA Kaufman ◽

M Pipas ◽

GJ Finn ◽

SE Mathews ◽

H Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Systemic Therapy ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Hormone Receptor Positive ◽

Prior Systemic Therapy

Download Full-text

Preoperative Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Preliminary Results of a Prospective, Phase 2 Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2016.11.030 ◽

2017 ◽

Vol 97 (4) ◽

pp. 747-753 ◽

Cited By ~ 15

Author(s):

Elizabeth Nichols ◽

Susan B. Kesmodel ◽

Emily Bellavance ◽

Cynthia Drogula ◽

Katherine Tkaczuk ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Accelerated Partial Breast Irradiation ◽

Partial Breast Irradiation ◽

Phase 2 ◽

Breast Irradiation ◽

Preliminary Results ◽

Phase 2 Trial ◽

Prospective Phase

Download Full-text

First Results of a Phase 2 Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2016.06.032 ◽

2016 ◽

Vol 96 (2) ◽

pp. S7 ◽

Cited By ~ 1

Author(s):

A.E. Dragun ◽

N.J. Ajkay ◽

E.C. Riley ◽

T. Roberts ◽

J. Pan ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Breast Irradiation ◽

Phase 2 Trial ◽

First Results

Download Full-text

Faculty of 1000 evaluation for Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717985574.793472568 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Hormone Receptor Positive ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer

10.1158/1538-7445.sabcs17-pd5-04 ◽

2018 ◽

Author(s):

E de Azambuja ◽

C Saura ◽

P Nuciforo ◽

S Frantal ◽

M Oliveira ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Early Stage ◽

Blind Study ◽

Early Stage Breast Cancer ◽

Double Blind Study ◽

Double Blind ◽

Er Positive

Download Full-text

Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”

10.1158/1538-7445.sabcs17-p3-12-01 ◽

2018 ◽

Cited By ~ 1

Author(s):

P Sánchez-Rovira ◽

AL Hirschberg ◽

M Gil-Gil ◽

S Antolín-Novoa ◽

L García-Estévez ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Early Stage ◽

Controlled Study ◽

Adjuvant Setting ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Download Full-text

Abstract OT1-02-01: A randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early stage breast cancer

10.1158/1538-7445.sabcs19-ot1-02-01 ◽

2020 ◽

Author(s):

Signe Borgquist ◽

Maj-Britt Jensen ◽

Marianne Ewertz ◽

Anders Bonde Jensen ◽

Thomas P. Ahern ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Phase 2 Trial of Accelerated, Hypofractionated Whole-Breast Irradiation of 39Gy in 13 Fractions Followed by a Tumor Bed Boost Sequentially Delivering 9Gy in 3 Fractions in Early-Stage Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2014.04.033 ◽

2014 ◽

Vol 25 (2) ◽

pp. 164-165

Author(s):

R. Gopal

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Whole Breast Irradiation ◽

Phase 2 ◽

Breast Irradiation ◽

Tumor Bed ◽

Phase 2 Trial ◽

Tumor Bed Boost ◽

Hypofractionated Whole Breast Irradiation

Download Full-text